Novartis
After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
1 November 2021
Around 10% of people in the United Kingdom (UK) have chronic kidney disease (CKD) according to Kidney Care UK. While CKD can be managed through diet and…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
Gene therapies represent a paradigm shift in medicine, with the potential to address the root causes of chronic diseases. They offer one-time treatment regimens and, in some cases, potentially a cure. As a result, they offer transformative value for patients, physicians, health systems and society. However, with the prospect of more gene therapy approvals there is concern in Europe that these technologies could threaten the financial sustainability of health systems.
The Promise of Gene Therapies: Are We Ready?
1 April 2021
In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In this interactive report we highlight our 5 key takeaways from the debate with clips, quotes and highlights.